HC Wainwright Issues Negative Outlook for CADL Earnings

Candel Therapeutics, Inc. (NASDAQ:CADL) – Research analysts at HC Wainwright dropped their Q3 2026 earnings per share (EPS) estimates for Candel Therapeutics in a research report issued on Thursday, August 13th. HC Wainwright analyst A. Maldonado now forecasts that the company will earn ($0.35) per share for the quarter, down from their previous forecast of ($0.25). HC Wainwright currently has a “Buy” rating and a $23.00 target price on the stock. The consensus estimate for Candel Therapeutics’ current full-year earnings is ($1.30) per share. HC Wainwright also issued estimates for Candel Therapeutics’ Q4 2026 earnings at ($0.30) EPS, FY2026 earnings at ($1.33) EPS, FY2027 earnings at ($0.19) EPS and FY2030 earnings at $2.07 EPS.

Candel Therapeutics (NASDAQ:CADL) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.28).

Several other research firms have also recently issued reports on CADL. Wall Street Zen cut shares of Candel Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday. UBS Group restated a “buy” rating on shares of Candel Therapeutics in a research report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Candel Therapeutics in a report on Friday, July 17th. Stifel Nicolaus assumed coverage on shares of Candel Therapeutics in a report on Monday, July 13th. They issued a “buy” rating and a $22.00 price target on the stock. Finally, Bank of America increased their price objective on Candel Therapeutics from $9.00 to $12.00 and gave the stock a “neutral” rating in a research report on Friday, August 14th. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $19.29.

Candel Therapeutics Price Performance

Shares of NASDAQ:CADL opened at $12.05 on Monday. The company has a 50 day moving average of $9.82 and a 200 day moving average of $7.50. The stock has a market cap of $922.05 million, a P/E ratio of -8.55 and a beta of -0.51. Candel Therapeutics has a 12 month low of $4.35 and a 12 month high of $12.48. The company has a current ratio of 16.09, a quick ratio of 16.09 and a debt-to-equity ratio of 0.38.

Institutional Trading of Candel Therapeutics

Hedge funds have recently made changes to their positions in the stock. Moneta Group Investment Advisors LLC boosted its holdings in shares of Candel Therapeutics by 4.9% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 42,517 shares of the company’s stock worth $240,000 after purchasing an additional 2,000 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Candel Therapeutics by 29.0% during the 4th quarter. Invesco Ltd. now owns 15,039 shares of the company’s stock valued at $85,000 after buying an additional 3,380 shares in the last quarter. Janney Montgomery Scott LLC raised its holdings in shares of Candel Therapeutics by 12.6% during the 1st quarter. Janney Montgomery Scott LLC now owns 30,472 shares of the company’s stock valued at $149,000 after buying an additional 3,400 shares in the last quarter. MetLife Investment Management LLC raised its holdings in shares of Candel Therapeutics by 25.5% during the 4th quarter. MetLife Investment Management LLC now owns 19,443 shares of the company’s stock valued at $110,000 after buying an additional 3,955 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its position in Candel Therapeutics by 128.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company’s stock worth $40,000 after buying an additional 4,439 shares during the last quarter. 13.93% of the stock is owned by institutional investors.

Insider Activity at Candel Therapeutics

In related news, CTO Seshu Tyagarajan sold 7,000 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $10.02, for a total value of $70,140.00. Following the sale, the chief technology officer directly owned 83,865 shares of the company’s stock, valued at $840,327.30. This trade represents a 7.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Francesca Barone sold 23,447 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $10.06, for a total transaction of $235,876.82. Following the completion of the sale, the insider directly owned 77,362 shares in the company, valued at $778,261.72. This represents a 23.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 14.30% of the stock is currently owned by corporate insiders.

About Candel Therapeutics

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.